GRAIL, Inc. (GRAL) Q2 FY26 Earnings Call

Galleri volume growth remains strong; FDA approval and reimbursement remain central milestones. [5][4]

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-05
Length47 minutes
EPS$-2.56
EPS consensus$-2.91
Revenue$40.8M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

All GRAL earnings ยท Back to GRAL overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.